2-(4-pyridyl)-5-(4-chlorophenyl)-3-(5-bromo-2-propyloxyphenyl)pyrrole,
L 168,049,
L 168049,
L-168,049,
L-168049,
L-168,049,
191034-25-0,
Glucagon Receptor Antagonist II,
CHEMBL351772,
L-168049,
4-[3-(5-bromo-2-propoxyphenyl)-5-(4-chlorophenyl)-1H-pyrrol-2-yl]pyridine,
2-(4-Pyridyl)-5-(4-Chlorophenyl)-3-(5-Bromo-2-Propyloxyphenyl)Pyrrole,
AC1NSKCK,
GTPL3505,
SCHEMBL6362882,
CHEBI:92326,
CTK8E7931,
DTXSID10415520,
HMS3268L08,
HMS3677E10,
BDBM50075775,
BN0285,
ZINC37866152,
AKOS024457045,
NCGC00092367-01,
RT-013470,
B7014,
L000331,
L168049,
J-012341,
L 168049,
BRD-K18036262-001-01-0,
4-[3-(5-Bromo-2-propoxy-phenyl)-5-(4-chloro-phenyl)-1H-pyrrol-2-yl]-pyridine,
Pyridine, 4-[3-(5-bromo-2-propoxyphenyl)-5-(4-chlorophenyl)-1H-pyrrol-2-yl]-,
dapt,
D0M3AR,
Glucagon antagonists (diabetes),
CID5311276,
SCH-900822,
Glucagon antagonists (diabetes), Merck & Co,
208188-17-4,
208255-80-5,